Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 18, Issue 4, Pages 541-548Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780902845622
Keywords
angiogenesis; breast cancer; cancer chemotherapy; cancer prevention; copper chelation; head and neck cancer; NF-kappa B; renal cell cancer; tetrathiomolybdate
Categories
Ask authors/readers for more resources
Background: Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappa B inhibition. Objective: This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies. Methods: A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review. Results/conclusions: Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and 11 clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available